Dermatology Department, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey.
Am J Clin Dermatol. 2010;11(1):51-4. doi: 10.2165/11311160-000000000-00000.
Treatment options for seborrheic dermatitis are numerous, including both topical and systemic agents (e.g. topical corticosteroids, oral antifungals, and psoralen plus UVA). However, long-term use of topical corticosteroids may lead to adverse effects. Pimecrolimus 1% cream is an effective and well tolerated treatment for seborrheic dermatitis.
To explore the efficacy of pimecrolimus 1% cream for the treatment of seborrheic dermatitis lesions resistant to conventional treatments.
Sixteen patients with resistant seborrheic dermatitis of the face applied pimecrolimus 1% cream twice daily for 2 weeks. The lesions were assessed clinically and the severity of the signs were assessed using a 4-point score. Additionally, the scores of all affected regions (paranasal, forehead, and eyebrows) were evaluated separately to assess whether different results would be obtained in different regions of the face. Also, patients completed self-assessments on a 100 mm Visual Analogue Scale (VAS) at each visit.
Statistically significant reductions in the scores of all parameters were observed at day 7 and day 14 of the study. There were no significant differences between the responses on the three regions of the face. No adverse effects were reported except for temporary pruritus immediately after the application of pimecrolimus 1% cream in one patient.
Although the interpretation of efficacy was limited by the open-label, non-controlled study design and the small number of patients, this trial suggests that pimecrolimus 1% cream may be a successful treatment choice for patients with resistant seborrheic dermatitis of the face.
脂溢性皮炎的治疗方法众多，包括局部和系统治疗药物（如局部皮质类固醇、口服抗真菌药和补骨脂素加 UVA）。然而，长期使用局部皮质类固醇可能导致不良反应。吡美莫司 1%乳膏是治疗脂溢性皮炎的有效且耐受性良好的药物。
探索吡美莫司 1%乳膏治疗常规治疗抵抗的脂溢性皮炎病变的疗效。
16 例面部脂溢性皮炎患者每天两次涂抹吡美莫司 1%乳膏，持续 2 周。通过临床评估和 4 分制评分评估病变严重程度。此外，还分别评估所有受累区域（鼻旁、前额和眉毛）的评分，以评估在面部不同区域是否会获得不同的结果。患者还在每次就诊时使用 100mm 视觉模拟量表（VAS）进行自我评估。
研究第 7 天和第 14 天，所有参数的评分均显著降低。面部三个区域的反应无显著差异。除一名患者在使用吡美莫司 1%乳膏后立即出现短暂瘙痒外，无其他不良反应报告。
尽管由于开放性、非对照研究设计和患者数量较少，对疗效的解释受到限制，但该试验表明吡美莫司 1%乳膏可能是面部抵抗性脂溢性皮炎患者的成功治疗选择。
